Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial
Ben J. Slotman*, Corinne Faivre-Finn, Harm van Tinteren, Astrid Keijserd, John Praag, Joost Knegjens, Matthew Hatton, Iris van Dam, Annija van der Leest, Bart Reymen, Jos Stigt, Kate Haslett, Devashish Tripathi, Egbert F. Smit, Suresh Senan
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial'. Together they form a unique fingerprint.